Targeting AR positive prostate cancer cells by the novel P300/CBP oral available PROTAC degrader

被引：0
|
作者：
Luo, Jie
Prolia, Abhijit
Qiao, Yuanyuan
Tian, Jean
Mannan, Rahul
Mahapatra, Somnath
Chen, Zhixiang
Seri, Rithvik
Wang, Shaomeng
Chinnaiyan, Arul
机构：
来源：
CANCER RESEARCH | 2023年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-6048
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6048
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer
    Han, Xin
    Wang, Chao
    Qin, Chong
    Xiang, Weiguo
    Fernandez-Salas, Ester
    Yang, Chao-Yie
    Wang, Mi
    Zhao, Lijie
    Xu, Tianfeng
    Chinnaswamy, Krishnapriya
    Delproposto, James
    Stuckey, Jeanne
    Wang, Shaomeng
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (02) : 941 - 964
  • [32] Targeting pancreatic cancer organoids with dual BET and CBP/P300 inhibitor NEO2734
    Radulovich, Nikolina
    Tamblyn, Laura
    Seo, Heewon
    Haibe-Kains, Benjamin
    Lupien, Mathieu
    Gilles, Francis
    Tsao, Ming S.
    CANCER RESEARCH, 2019, 79 (24)
  • [33] Androgen receptor (AR) interaction with acetyltransferase p300 in normal and prostate tumor cells
    Narayanan, BA
    Narayanan, NK
    Re, GG
    Yang, Y
    MOLECULAR BIOLOGY OF THE CELL, 2002, 13 : 101A - 101A
  • [34] HISTONE DEACETYLASE (HDAC1) AND HISTONE ACETYLTRANSFERASE (CBP/P300) IN THE PATHOGENESIS OF PROSTATE CANCER
    Abbas, Ata
    Shukla, Sanjeev
    Umar, Saleem
    MacLennan, Gregory T.
    Gupta, Sanjay
    JOURNAL OF UROLOGY, 2009, 181 (04): : 393 - 393
  • [35] Melatonin regulates oral cancer cell migration by suppressing histone acetylation on the CBP/P300 gene
    Yang, S. F.
    Lin, C. W.
    Yeh, C. M.
    EUROPEAN JOURNAL OF CANCER, 2016, 61 : S50 - S50
  • [36] Androgen deprivation increases p300 expression in prostate cancer cells
    Heemers, Hannelore V.
    Sebo, Thomas J.
    Debes, Jose D.
    Regan, Kevin M.
    Raclaw, Kristin A.
    Murphy, Linda M.
    Hobisch, Alfred
    Culig, Zoran
    Tindall, Donald J.
    CANCER RESEARCH, 2007, 67 (07) : 3422 - 3430
  • [37] Targeting CDCP1 gene transcription coactivated by BRD4 and CBP/p300 in castration-resistant prostate cancer
    Donglei Ji
    Guanglei Shang
    Enwei Wei
    Yanjie Jia
    Chunyu Wang
    Qiang Zhang
    Lei Zeng
    Oncogene, 2022, 41 : 3251 - 3262
  • [38] Targeting CDCP1 gene transcription coactivated by BRD4 and CBP/p300 in castration-resistant prostate cancer
    Ji, Donglei
    Shang, Guanglei
    Wei, Enwei
    Jia, Yanjie
    Wang, Chunyu
    Zhang, Qiang
    Zeng, Lei
    ONCOGENE, 2022, 41 (23) : 3251 - 3262
  • [39] Characterisation of CCS1477: A novel small molecule inhibitor of p300/CBP for the treatment of castration resistant prostate cancer.
    Pegg, Neil
    Brooks, Nigel
    Worthington, Jenny
    Young, Barbara
    Prosser, Amy
    Lane, Jordan
    Taddei, David
    Brown, Richard
    Harbottle, Gareth
    Shannon, Jonathan
    Paoletta, Silvia
    Knudsen, Karen E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [40] Discovery of CBPD-409 and CBPD-268 as highly potent and orally efficacious CBP/p300 PROTAC degraders for the treatment of castration-resistant prostate cancer
    Chen, Zhixiang
    Wang, Mi
    Wu, Dimin
    Zhao, Lijie
    Xu, Tianfeng
    Metwally, Hoda
    Wang, Yu
    McEachern, Donna
    Jiang, Wei
    Bai, Longchuan
    Luo, Jie
    Wang, Meilin
    Li, Ruiting
    Takyi-Williams, John
    Wang, Lu
    Li, Qiuxia
    Wen, Bo
    Sun, Duxin
    Chinnaiyan, Arul M.
    Wang, Shaomeng
    CANCER RESEARCH, 2024, 84 (06)
12345